p27 immunostaining is related to prognosis in malignant mesothelioma

Histopathology

Volumn 38, Issue 6, 2001, Pages 535-541

  Beer, T W ^a,c   Shepherd, P ^a   Pullinger, N C ^b  

^a Royal Haslar Hospital   (United Kingdom)

^b INSTITUTE OF NAVAL MEDICINE   (United Kingdom)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Malignant mesothelioma; p27; Prognosis

Indexed keywords

KI 67 ANTIGEN; PROTEIN; PROTEIN P27; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MITOSIS INDEX; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; SURVIVAL TIME;

ANTIGENS, NUCLEAR; APOPTOSIS; BIOLOGICAL MARKERS; CELL COUNT; COUNSELING; HUMANS; KI-67 ANTIGEN; MESOTHELIOMA; MICROFILAMENT PROTEINS; MITOTIC INDEX; MUSCLE PROTEINS; NUCLEAR PROTEINS; PLEURAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 0034826716     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2001.01136.x     Document Type: Article

References (31)

1. Prognosis in malignant mesothelioma related to MIB-1 proliferation index and histological subtype
2. Prognostic factors of malignant mesothelioma of the pleura
3. Malignant mesothelioma 1982: Review of 4710 published cases
4. The mesothelioma epidemic
5. Mitotic and apoptotic activity in malignant mesothelioma using in-situ end labelling
6. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
7. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis staging
8. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers
9. Cancer prognostics: Past, present and p27
10. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
11. Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma
12. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
13. Kip1
14. Kip1 expression in colorectal cancer: A clinico-pathological characterisation
15. Kip1 is associated with progression and lymph node metastasis of gastric carcinoma
16. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
17. Loss or altered subcellular localisation of p27 in Barrett's associated adenocarcinoma
18. Asymptotically efficient rank invariant procedures
19. Multimodality management of malignant pleural mesothelioma
20. Diagnosis and prognosis of malignant mesothelioma
21. Diagnosis and prognosis in malignant mesothelioma: A prospective study
22. Syndecan-1 expression in malignant mesothelioma: Correlation with cell differentiation, WT1 expression, and clinical outcome
23. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma
24. Low p27 expression predicts poor disease-free survival in patients with prostate cancer
25. kip1 and Ki-67 in benign and malignant thyroid tumours
26. Expression of p-27 (kip1) in nevi and melanomas
27. kip1 and apoptosis in tumour cells on the overall survival of patients with non-early stage gastric carcinoma
28. Kip1 expression in normal and neoplastic cervical epithelium